-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor’s note iNature is China’s largest academic official account.
It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature Talent Official Account is now launched, focusing on talent recruitment, academic progress, scientific research information, interested parties can Long press or scan the QR code below to follow us
.
iNature's single-dose program of HPV vaccine may solve many challenges by improving affordability, making vaccination programs logistically simpler and more flexible, and helping to weather the supply crisis
.
This study aims to describe the efficacy of a single-dose quadrivalent HPV vaccine in preventing occasional and persistent cervical HPV infection 10 years after vaccination compared with two or three doses of vaccine
.
On October 8, 2021, Partha Basu, the International Agency for Research on Cancer in Lyon, France, et al.
published online on Lancet Oncology entitled "Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study" research paper, which recruited vaccinated participants between September 1, 2009 and April 8, 2010, and was in the median Follow-up was conducted during the period of 9·0 years (IQR 8·2–9·6)
.
4348 participants received three doses, 4980 participants received two doses, and 4949 participants received one dose
.
Among participants with evaluable endpoints, the effectiveness of the vaccine against persistent HPV 16 and 18 infections in the single-dose default cohort (2135 women evaluated) was 95.
4% (95% CI 85·0–99·9) ), 93.
1% (77·3–99.
8) in the two-dose cohort (1452 women were evaluated), and 93.
3% (77 ·5-99·7)
.
In short, a single dose of HPV vaccine can provide similar protection as two or three doses of vaccine, preventing persistent infection with HPV 16 and 18 (the genotype that causes nearly 70% of cervical cancer)
.
On October 1, 2020, Lei Jiayao (English translation, English translation, Lei Jiayao) of Karolinska Institute in Sweden published a study titled "HPV Vaccination and the Risk of Invasive Cervical Cancer" in the top international medical journal NEJM as a newsletter The paper, the study used Sweden's national demographic and health status registry to track the open population of 1,672,983 girls and women between the ages of 10 and 30 from 2006 to 2017
.
The study assessed the association between HPV vaccination and the risk of invasive cervical cancer
.
The study found that among vaccinated women, the cumulative incidence of cervical cancer was 47 cases per 100,000 people, and 94 cases per 100,000 people among unvaccinated women
.
After adjusting the follow-up age, the incidence rate of comparing the vaccinated population with the unvaccinated population is 0.
51
.
After additional adjustments for other covariates, the incidence rate was 0.
37
.
After adjusting for all covariates, the incidence rate was 0.
12 among women who were vaccinated before the age of 17, and 0.
47 among women who were vaccinated between the ages of 17 and 30
.
In conclusion, among girls and women between 10 and 30 years old in Sweden, quadrivalent HPV vaccination in the population can greatly reduce the risk of invasive cervical cancer (click to read)
.
On June 26, 2019, Mélanie Drolet and others from the University of Quebec in Canada published an online publication entitled "Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis" in the international top medical journal Lancet.
The research paper, this updated systematic review and meta-analysis includes follow-up data from 60 million people and 8 years after vaccination
.
The study found that the HPV vaccination program had a substantial impact on HPV infection, CIN2+ in girls and women, and anogenital warts in girls, women, boys, and men
.
In addition, plans with multi-group vaccination and high vaccination coverage have greater direct impact and group effects (click to read)
.
Cervical cancer vaccine, also known as HPV vaccine, is a type of vaccine that can prevent human papillomavirus (HPV) infection
.
Medical research shows that 99.
7% of cervical cancers are caused by the HPV virus
.
It is generally recognized internationally that HPV vaccine has a preventive effect on women aged 9-45.
If women can inject HPV vaccine before their first sex, it will reduce the incidence of cervical cancer and precancerous lesions by 90%
.
Currently, there are three types of HPV vaccines on the market: bivalent, quadrivalent, and ninth valence.
The "valence" represents the type of virus that the vaccine can prevent
.
The bivalent vaccine can prevent infection by HPV16 and HPV18 viruses
.
International research data shows that more than 70% of cervical cancers are caused by these two viruses, and the bivalent vaccine is only suitable for women's vaccination
.
Quadrivalent is suitable for men and women over nine years of age.
It can effectively prevent four types of HPV virus, namely 6, 11, 16, and 18.
It can prevent more than 70% of cervical cancer and more than 70% of condyloma acuminata
.
The nine-valent vaccine is also suitable for men and women over nine years of age.
There are nine types of HPV viruses that can be prevented, namely: 6, 11, 16, 18, 31, 3, 45, 52, and 58.
It can prevent more than 90% of condyloma acuminata and more than 90% of cervical cancer, and other related diseases
.
Previous studies of HPV vaccines (including randomized trials evaluating efficacy or effectiveness) have shown that these vaccines can prevent HPV infection, condyloma acuminatum, and precancerous cervical lesions
.
The efficacy of the quadrivalent human papillomavirus (HPV) vaccine in preventing cervical lesions has been shown
.
However, there is a lack of data on the relationship between tetravalent HPV vaccination and subsequent risk of invasive cervical cancer
.
The study used Sweden's national demographic and health status registry to track the open population of 1,672,983 girls and women between the ages of 10 and 30 from 2006 to 2017
.
The study assessed the association between HPV vaccination and the risk of invasive cervical cancer
.
During the study period, girls and women were assessed for cervical cancer until their 31st birthday
.
Cervical cancer was diagnosed in 19 women who received the quadrivalent HPV vaccine and 538 women who did not receive the vaccine
.
Among vaccinated women, the cumulative incidence of cervical cancer is 47 cases per 100,000 people, and 94 cases per 100,000 women who have not been vaccinated
.
After adjusting the follow-up age, the incidence rate of comparing the vaccinated population with the unvaccinated population is 0.
51
.
After additional adjustments for other covariates, the incidence rate was 0.
37
.
After adjusting for all covariates, the incidence rate was 0.
12 among women who were vaccinated before the age of 17, and 0.
47 among women who were vaccinated between the ages of 17 and 30
.
In conclusion, among girls and women between 10 and 30 years old in Sweden, quadrivalent HPV vaccination in the population can greatly reduce the risk of invasive cervical cancer
.
Reference message: https://
It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature Talent Official Account is now launched, focusing on talent recruitment, academic progress, scientific research information, interested parties can Long press or scan the QR code below to follow us
.
iNature's single-dose program of HPV vaccine may solve many challenges by improving affordability, making vaccination programs logistically simpler and more flexible, and helping to weather the supply crisis
.
This study aims to describe the efficacy of a single-dose quadrivalent HPV vaccine in preventing occasional and persistent cervical HPV infection 10 years after vaccination compared with two or three doses of vaccine
.
On October 8, 2021, Partha Basu, the International Agency for Research on Cancer in Lyon, France, et al.
published online on Lancet Oncology entitled "Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study" research paper, which recruited vaccinated participants between September 1, 2009 and April 8, 2010, and was in the median Follow-up was conducted during the period of 9·0 years (IQR 8·2–9·6)
.
4348 participants received three doses, 4980 participants received two doses, and 4949 participants received one dose
.
Among participants with evaluable endpoints, the effectiveness of the vaccine against persistent HPV 16 and 18 infections in the single-dose default cohort (2135 women evaluated) was 95.
4% (95% CI 85·0–99·9) ), 93.
1% (77·3–99.
8) in the two-dose cohort (1452 women were evaluated), and 93.
3% (77 ·5-99·7)
.
In short, a single dose of HPV vaccine can provide similar protection as two or three doses of vaccine, preventing persistent infection with HPV 16 and 18 (the genotype that causes nearly 70% of cervical cancer)
.
On October 1, 2020, Lei Jiayao (English translation, English translation, Lei Jiayao) of Karolinska Institute in Sweden published a study titled "HPV Vaccination and the Risk of Invasive Cervical Cancer" in the top international medical journal NEJM as a newsletter The paper, the study used Sweden's national demographic and health status registry to track the open population of 1,672,983 girls and women between the ages of 10 and 30 from 2006 to 2017
.
The study assessed the association between HPV vaccination and the risk of invasive cervical cancer
.
The study found that among vaccinated women, the cumulative incidence of cervical cancer was 47 cases per 100,000 people, and 94 cases per 100,000 people among unvaccinated women
.
After adjusting the follow-up age, the incidence rate of comparing the vaccinated population with the unvaccinated population is 0.
51
.
After additional adjustments for other covariates, the incidence rate was 0.
37
.
After adjusting for all covariates, the incidence rate was 0.
12 among women who were vaccinated before the age of 17, and 0.
47 among women who were vaccinated between the ages of 17 and 30
.
In conclusion, among girls and women between 10 and 30 years old in Sweden, quadrivalent HPV vaccination in the population can greatly reduce the risk of invasive cervical cancer (click to read)
.
On June 26, 2019, Mélanie Drolet and others from the University of Quebec in Canada published an online publication entitled "Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis" in the international top medical journal Lancet.
The research paper, this updated systematic review and meta-analysis includes follow-up data from 60 million people and 8 years after vaccination
.
The study found that the HPV vaccination program had a substantial impact on HPV infection, CIN2+ in girls and women, and anogenital warts in girls, women, boys, and men
.
In addition, plans with multi-group vaccination and high vaccination coverage have greater direct impact and group effects (click to read)
.
Cervical cancer vaccine, also known as HPV vaccine, is a type of vaccine that can prevent human papillomavirus (HPV) infection
.
Medical research shows that 99.
7% of cervical cancers are caused by the HPV virus
.
It is generally recognized internationally that HPV vaccine has a preventive effect on women aged 9-45.
If women can inject HPV vaccine before their first sex, it will reduce the incidence of cervical cancer and precancerous lesions by 90%
.
Currently, there are three types of HPV vaccines on the market: bivalent, quadrivalent, and ninth valence.
The "valence" represents the type of virus that the vaccine can prevent
.
The bivalent vaccine can prevent infection by HPV16 and HPV18 viruses
.
International research data shows that more than 70% of cervical cancers are caused by these two viruses, and the bivalent vaccine is only suitable for women's vaccination
.
Quadrivalent is suitable for men and women over nine years of age.
It can effectively prevent four types of HPV virus, namely 6, 11, 16, and 18.
It can prevent more than 70% of cervical cancer and more than 70% of condyloma acuminata
.
The nine-valent vaccine is also suitable for men and women over nine years of age.
There are nine types of HPV viruses that can be prevented, namely: 6, 11, 16, 18, 31, 3, 45, 52, and 58.
It can prevent more than 90% of condyloma acuminata and more than 90% of cervical cancer, and other related diseases
.
Previous studies of HPV vaccines (including randomized trials evaluating efficacy or effectiveness) have shown that these vaccines can prevent HPV infection, condyloma acuminatum, and precancerous cervical lesions
.
The efficacy of the quadrivalent human papillomavirus (HPV) vaccine in preventing cervical lesions has been shown
.
However, there is a lack of data on the relationship between tetravalent HPV vaccination and subsequent risk of invasive cervical cancer
.
The study used Sweden's national demographic and health status registry to track the open population of 1,672,983 girls and women between the ages of 10 and 30 from 2006 to 2017
.
The study assessed the association between HPV vaccination and the risk of invasive cervical cancer
.
During the study period, girls and women were assessed for cervical cancer until their 31st birthday
.
Cervical cancer was diagnosed in 19 women who received the quadrivalent HPV vaccine and 538 women who did not receive the vaccine
.
Among vaccinated women, the cumulative incidence of cervical cancer is 47 cases per 100,000 people, and 94 cases per 100,000 women who have not been vaccinated
.
After adjusting the follow-up age, the incidence rate of comparing the vaccinated population with the unvaccinated population is 0.
51
.
After additional adjustments for other covariates, the incidence rate was 0.
37
.
After adjusting for all covariates, the incidence rate was 0.
12 among women who were vaccinated before the age of 17, and 0.
47 among women who were vaccinated between the ages of 17 and 30
.
In conclusion, among girls and women between 10 and 30 years old in Sweden, quadrivalent HPV vaccination in the population can greatly reduce the risk of invasive cervical cancer
.
Reference message: https://
